SEC Form 4 · accession 0001144204-18-047847
BRAINSTORM CELL THERAPEUTICS INC. · BCLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Arturo Araya
Officer — Chief Commercial Officer · Director
Period of report
Aug 28, 2018
Accepted (ET)
Sep 4, 2018 · 5:02 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001137883
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Aug 28, 2018 | D | 2,805 | $0.00 | D | 5,608 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $3.98 | Aug 28, 2018 | A | 200,000 | A | Aug 28, 2019 | Aug 27, 2028 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F1Represents unvested shares of restricted common stock awarded by Issuer to Reporting Person on February 26, 2018 and March 26, 2018, forfeited pursuant to Reporting Person's August 28, 2018 employment agreement with Issuer.
- F2Option shall vest and become exercisable as to 25% of the underlying shares on each of the first, second, third and fourth anniversary of the date of grant, until fully vested and exercisable on the fourth anniversary of the date of grant, provided Reporting Person remains employed by Issuer from the date of grant through each applicable vesting date.